Stilbene derivatives that are colchicine site microtubule inhibitors have antileukemic activity and minimal systemic toxicity

被引:20
作者
Cao, Thai M. [2 ]
Durrant, David [1 ]
Tripathi, Ashutosh [3 ,4 ]
Liu, Jihua [2 ]
Tsai, Schickwann [2 ]
Kellogg, Glen E. [3 ,4 ]
Simoni, Daniele [5 ]
Lee, Ray M. [1 ]
机构
[1] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA
[2] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA
[3] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA
[4] Virginia Commonwealth Univ, Inst Struct Biol & Drug Discovery, Richmond, VA 23298 USA
[5] Univ Ferrara, Dipartimento Sci Farmaceut, I-44100 Ferrara, Italy
关键词
D O I
10.1002/ajh.21104
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Stilbenes are a group of natural compounds with many biological activities. Two highly potent stilbenes, cis-3,4',5-trimethoxy-3'-aminostilbene (stilbene 5c) and cis-3,4,5-trimethoxy-3-hydroxystilbene (stilbene 6c) induce G(2)/M cell-cycle arrest and leukemic cell death in nanomolarity range without affecting normal bone marrow progenitor cells. The mechanism of stilbenes is mediated by interfering with microtubule polymerization through the colchicine-binding site. Docking of the stilbenes into tubulin structure confirms that stilbenes fit into the colchicine-binding pocket. Animal studies show that stilbenes are well tolerated in mice and are capable of inducing more than 50% leukemic cell death by a single dose injection. A 5-day treatment with low-dose stilbenes suppresses tumor growth in mice with established tumor xenografts. No major organ damage was detected by histological section. Our results indicate that stilbene 5c is a microtubule-interfering agent and can be potentially useful in leukemic therapy.
引用
收藏
页码:390 / 397
页数:8
相关论文
共 40 条
[1]   Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate [J].
Anderson, HL ;
Yap, JT ;
Miller, MP ;
Robbins, A ;
Jones, T ;
Price, PM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2823-2830
[2]   Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer [J].
Azios, NG ;
Dharmawardhane, SF .
NEOPLASIA, 2005, 7 (02) :128-140
[3]   Resveratrol improves health and survival of mice on a high-calorie diet [J].
Baur, Joseph A. ;
Pearson, Kevin J. ;
Price, Nathan L. ;
Jamieson, Hamish A. ;
Lerin, Carles ;
Kalra, Avash ;
Prabhu, Vinayakumar V. ;
Allard, Joanne S. ;
Lopez-Lluch, Guillermo ;
Lewis, Kaitlyn ;
Pistell, Paul J. ;
Poosala, Suresh ;
Becker, Kevin G. ;
Boss, Olivier ;
Gwinn, Dana ;
Wang, Mingyi ;
Ramaswamy, Sharan ;
Fishbein, Kenneth W. ;
Spencer, Richard G. ;
Lakatta, Edward G. ;
Le Couteur, David ;
Shaw, Reuben J. ;
Navas, Placido ;
Puigserver, Pere ;
Ingram, Donald K. ;
de Cabo, Rafael ;
Sinclair, David A. .
NATURE, 2006, 444 (7117) :337-342
[4]   Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors [J].
Beerepoot, LV ;
Radema, SA ;
Witteveen, EO ;
Thomas, T ;
Wheeler, C ;
Kempin, S ;
Voest, EE .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (10) :1491-1498
[5]   Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4′-trimethoxystilbene [J].
Belleri, M ;
Ribatti, D ;
Nicoli, S ;
Cotelli, F ;
Forti, L ;
Vannini, V ;
Stivala, LA ;
Presta, M .
MOLECULAR PHARMACOLOGY, 2005, 67 (05) :1451-1459
[6]   Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice [J].
Cao, TM ;
Lo, B ;
Ranheim, EA ;
Grumet, FC ;
Shizuru, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (20) :11571-11576
[7]   Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer [J].
Cooney, MM ;
Radivoyevitch, T ;
Dowlati, A ;
Overmoyer, B ;
Levitan, N ;
Robertson, K ;
Levine, SL ;
DeCaro, K ;
Buchter, C ;
Taylor, A ;
Stambler, BS ;
Remick, SC .
CLINICAL CANCER RESEARCH, 2004, 10 (01) :96-100
[8]  
Dowlati A, 2002, CANCER RES, V62, P3408
[9]   Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling [J].
Fulda, S ;
Debatin, KM .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (05) :786-798
[10]   Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging [J].
Galbraith, SM ;
Maxwell, RJ ;
Lodge, MA ;
Tozer, GM ;
Wilson, J ;
Taylor, NJ ;
Stirling, JJ ;
Sena, L ;
Padhani, AR ;
Rustin, GJS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2831-2842